Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 6,005	$ 15,045
Prepaid expenses and other current assets	657	1,381
Total Current Assets	6,662	16,426
Property and equipment, net	202	367
Right of use asset	316	419
Deposits and other assets	23	23
Total Assets	7,203	17,235
Current Liabilities:
Accounts payable	992	2,315
Accrued expenses	988	1,776
Accrued employee benefits	752	935
Lease liability	278	249
Total Current Liabilities	3,010	5,275
Lease liability - Long term	261	473
Total Liabilities	3,271	5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,733	12,544
Stockholders' Deficit:
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 4,146 issued and outstanding and 7,638 issued and outstanding	2,584	4,761
Common Stock, $0.001 par value; 200,000,000 shares authorized, 19,845,283 and 16,808,758 issued and 19,842,955 and 16,806,430 outstanding	20	17
Additional paid-in capital	236,320	232,580
Accumulated deficit	(244,975)	(235,537)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit	(6,051)	1,821
Non-controlling interest	(2,750)	(2,878)
Total Stockholders' Deficit	(8,801)	(1,057)
Total Liabilities and Stockholders' Deficit	$ 7,203	$ 17,235